ChemicalBook > CAS DataBase List > BAY 60-7550

BAY 60-7550

Product Name
BAY 60-7550
CAS No.
439083-90-6
Chemical Name
BAY 60-7550
Synonyms
BAY 60-7550;2-(3,4-Dimethoxybenzyl)-7-((2R,3R)-2-hydroxy-6-phenylhexan-3-yl)-5-methylimidazo[5,1-f][1,2,4];2-[(3,4-Dimethoxyphenyl)methyl]-7-[(1R)-1-[(1R)-1-hydroxyethyl]-4-phenylbutyl]-5-methyl-imidazo[5,1-f][1,2,4]triazin-4(1H)-one;Imidazo[5,1-f][1,2,4]triazin-4(1H)-one, 2-[(3,4-dimethoxyphenyl)methyl]-7-[(1R)-1-[(1R)-1-hydroxyethyl]-4-phenylbutyl]-5-methyl-
CBNumber
CB0829889
Molecular Formula
C27H32N4O4
Formula Weight
476.57
MOL File
439083-90-6.mol
More
Less

BAY 60-7550 Property

Boiling point:
680.7±65.0 °C(Predicted)
Density 
1.24±0.1 g/cm3(Predicted)
storage temp. 
-20°C
solubility 
DMSO:21.65(Max Conc. mg/mL);45.43(Max Conc. mM)
Ethanol:10.0(Max Conc. mg/mL);20.98(Max Conc. mM)
form 
powder
pka
14.54±0.20(Predicted)
color 
white to light brown
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
SML2311
Product name
BAY 60-7550
Purity
≥95% (HPLC)
Packaging
5mg
Price
$257
Updated
2024/03/01
Sigma-Aldrich
Product number
SML2311
Product name
BAY 60-7550
Purity
≥95% (HPLC)
Packaging
25mg
Price
$390
Updated
2024/03/01
Cayman Chemical
Product number
10011135
Product name
BAY 60-7550
Purity
≥95%
Packaging
1mg
Price
$93
Updated
2024/03/01
Cayman Chemical
Product number
10011135
Product name
BAY 60-7550
Purity
≥95%
Packaging
5mg
Price
$242
Updated
2024/03/01
Cayman Chemical
Product number
10011135
Product name
BAY 60-7550
Purity
≥95%
Packaging
10mg
Price
$437
Updated
2024/03/01
More
Less

BAY 60-7550 Chemical Properties,Usage,Production

Description

The second messengers cAMP and cGMP are important mediators of signal transduction and hence a wide range of cellular processes including vasodilation and synaptic plasticity. Type 2 cyclic nucleotide phosphodiesterases (PDE2) isoforms inactivate cAMP and cGMP by hydrolyzing the phosphodiester bond. BAY 60-7550 is a potent PDE2 inhibitor with IC50 values of 2.0 nM (bovine) and 4.7 nM (human). It is 50-fold more selective for PDE2 compared to PDE1 and greater than 100-fold selective compared to PDE5 PDE3B, PDE4B, PDE7B, PDE8A, PDE9A, PDE10A, and PDE11A. At 3 mg/kg BAY 60-7550 antagonizes oxidative stress-induced anxiety-like behavioral effects in mice by increasing cGMP signaling. At 1 mg/kg BAY 60-7550 improves the performance of rats in an object location task, enhancing cAMP/cGMP-mediated object and spatial memory consolidation.

Uses

The compound induced anxiety by inhibition of Phosphodiesterase-2 (PDE2), which regulates cGMP and cAMP signaling

Biochem/physiol Actions

BAY 60-7550 is an orally active, potent and selective cGMP-dependent phosphodiesterase PDE2 (PDE2A) inhibitor (human/bovine PDE2 IC50 = 4.7/2.0 nM; bovine PDE1 IC50 = 108 nM, human PDE5/5A/10A/4B IC50 = 240/580/704/940/1830 nM, human PDE3B/7B/8A/9A/11A IC50 >4 μM) with little activity (IC50 >10 μM) toward acetylcholinesterase, mAO-A/B, adenosine deaminase, and many receptor subtypes tested. Bay 60-7550 effectively upregulates cGMP and cAMP level in cultured rat and murine neurons (1 nM-1 μM) exposed to guanylyl cyclase (GC) or adenylyl cyclase (AC) stimulator (1 μM Bay 41-8543 or 2 μM forskolin), respectively, as well as exhibits learning and memory-improving efficacy in rats (0.6-3 mg/kg p.o.) and mice (0.3-1 mg/kg p.o.) in vivo.

Enzyme inhibitor

This selective cGMP/cAMP phosphodiesterase PDE2A inhibitor (FW = 476.60 g/mol; CAS 439083-90-6; Solubility: 10 mM DMSO), systematically named 2-[(3,4-dimethoxyphenyl)methyl]-7-[(1R)-1- hydroxyethyl]-4-phenylbutyl]-5-methyl-imidazo[5,1-f][1,2,4]triazin-4(1H)- one, targets Type 2 cyclic nucleotide phosphodiesterase (human, IC50 = 4.7 nM; bovine, IC50 = 2.0 nM), a dual-function enzyme that, when stimulated by 3’,5’-cyclicGMP (cGMP), preferentially catalyzes hydrolysis of 3’,5’- cyclicAMP (cAMP). BAY 60-7550 is 50x more selective for PDE2 than PDE1 and >100x selective relative to PDE5 PDE3B, PDE4B, PDE7B, PDE8A, PDE9A, PDE10A, and PDE11A. Use of BAY-60-7550 also indicates that PDE2 is responsible for the degradation of newly synthesized cGMP in cultured neurons and hippocampal slices. Inhibition of PDE2 enhanced long-term potentiation of synaptic transmission without altering basal synaptic transmission. Inhibition of PDE2 also improved the performance of rats in social and object recognition memory tasks, and reversed MK801-induced deficits in spontaneous alternation in mice in a T maze. Treatment of mice with L-buthionine-(S,R)-sulfoximine (300 mg/kg) induces oxidative stress and also causes anxiety-like behavioral effects in elevated plus-maze, open-field, and hole-board tests, most likely through the NADPH oxidase pathway. These effects are antagonized by Bay 60-7550 (3 mg/kg), which decreases oxidative stress and expression of NADPH oxidase subunits in amygdala, hypothalamus, and cultured neurons. The resulting increase in cGMP also promotes phosphorylation of vasodilator-stimulated phosphoprotein (VASP) at Ser-239, suggesting a role of cGMP-Protein Kinase G signaling in the reduction of anxiety. PDE inhibitors also enhance object recognition, and the effects of PDE inhibition on cognitive functions may result from higher cerebrovascular function. In the spatial location task, PDE5 inhibition of cGMP hydrolysis by vardenafil only enhances early-phase consolidation, and PDE4 inhibition of cAMP hydrolysis by rolipram only enhances late-phase consolidation; on the other hand, PDE2 inhibition of cAMP and cGMP hydrolysis by Bay 60- 7550, enhances both. These results underscore the specific effects of cAMP and cGMP on memory consolidation (object and spatial memory) and provide evidence that the underlying mechanisms of PDE inhibition on cognition are independent of cerebrovascular effects. Bay 60-7550 treatment also indicates that phosphodiesterase 2A is a major negative regulator of iNOS expression in lipopolysaccharide-treated mouse alveolar macrophages. BAY 60-7550 reverses functional impairments induced by brain ischemia by decreasing hippocampal neurodegeneration and enhancing hippocampal neuronal plasticity.

target

PDE2

BAY 60-7550 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

BAY 60-7550 Suppliers

MedChemexpress LLC
Tel
021-58955995
Fax
609-228-5909
Email
sales@medchemexpress.cn
Country
United States
ProdList
4861
Advantage
58
AdooQ BioScience, LLC
Tel
+1 (866) 930-6790
Fax
+1 (866) 333-9607
Email
info@adooq.com
Country
United States
ProdList
2782
Advantage
58
Musechem
Tel
+1-800-259-7612
Fax
+1-800-259-7612
Email
info@musechem.com
Country
United States
ProdList
4660
Advantage
60
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
32165
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
Aladdin Scientific
Tel
+1-+1(833)-552-7181
Email
sales@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58
Alfa Chemistry
Tel
--
Fax
--
Email
info@Alfa-Chemistry.com
Country
United States
ProdList
6814
Advantage
0
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81
United States Biological
Tel
--
Fax
--
Email
chemicals@usbio.net
Country
United States
ProdList
6214
Advantage
80
Creative Enzymes
Tel
--
Fax
--
Email
info@creative-enzymes.com
Country
United States
ProdList
6057
Advantage
58
MedChemExpress
Tel
--
Fax
--
Email
sales@medchemexpress.com
Country
United States
ProdList
6398
Advantage
58
Riedel-de Haen AG
Tel
--
Fax
--
Country
United States
ProdList
6773
Advantage
87
Matrix Scientific
Tel
--
Fax
--
Email
sales@matrixscientific.com
Country
United States
ProdList
6632
Advantage
80
Santa Cruz Biotechnology, Inc.
Tel
--
Fax
--
Email
scbt@scbt.com
Country
United States
ProdList
3597
Advantage
60
Fragmenta
Tel
--
Fax
--
Email
sales@fragmenta.com
Country
United States
ProdList
1068
Advantage
0

439083-90-6, BAY 60-7550Related Search:


  • BAY 60-7550
  • 2-(3,4-Dimethoxybenzyl)-7-((2R,3R)-2-hydroxy-6-phenylhexan-3-yl)-5-methylimidazo[5,1-f][1,2,4]
  • 2-[(3,4-Dimethoxyphenyl)methyl]-7-[(1R)-1-[(1R)-1-hydroxyethyl]-4-phenylbutyl]-5-methyl-imidazo[5,1-f][1,2,4]triazin-4(1H)-one
  • Imidazo[5,1-f][1,2,4]triazin-4(1H)-one, 2-[(3,4-dimethoxyphenyl)methyl]-7-[(1R)-1-[(1R)-1-hydroxyethyl]-4-phenylbutyl]-5-methyl-
  • 439083-90-6
  • Bases & Related Reagents
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Nucleotides
  • Pharmaceuticals
  • Cyclic Nucleotide related